These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34331108)

  • 41. The interplay between histone deacetylases and c-Myc in the transcriptional suppression of HPP1 in colon cancer.
    Wang J; Elahi A; Ajidahun A; Clark W; Hernandez J; Achille A; Hao JH; Seto E; Shibata D
    Cancer Biol Ther; 2014 Sep; 15(9):1198-207. PubMed ID: 24919179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
    Pal A; Leung JY; Ang GCK; Rao VK; Pignata L; Lim HJ; Hebrard M; Chang KT; Lee VK; Guccione E; Taneja R
    Elife; 2020 Nov; 9():. PubMed ID: 33252038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repurposing of posaconazole as a hedgehog/SMO signaling inhibitor for embryonal rhabdomyosarcoma therapy.
    Sun J; Lin W; Li C; Ueki H; Xue R; Sadahira T; Hu H; Wada K; Li N; Liu C; Araki M; Xu A; Huang P
    Am J Cancer Res; 2021; 11(9):4528-4540. PubMed ID: 34659903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
    Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
    Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strongylopus grayii tadpole blastema extract exerts cytotoxic effects on embryonal rhabdomyosarcoma cells.
    Harrison V; Khan SF; Damerell V; Bleloch J; ArulJothi KN; Sinkala M; Lennard K; Mulder N; Calder B; Blackburn J; Prince S
    In Vitro Cell Dev Biol Anim; 2022 Sep; 58(8):679-692. PubMed ID: 35947290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of RAS on the genesis of embryonal rhabdomyosarcoma.
    Langenau DM; Keefe MD; Storer NY; Guyon JR; Kutok JL; Le X; Goessling W; Neuberg DS; Kunkel LM; Zon LI
    Genes Dev; 2007 Jun; 21(11):1382-95. PubMed ID: 17510286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma.
    Chen EY; DeRan MT; Ignatius MS; Grandinetti KB; Clagg R; McCarthy KM; Lobbardi RM; Brockmann J; Keller C; Wu X; Langenau DM
    Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5349-54. PubMed ID: 24706870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.
    Vella S; Pomella S; Leoncini PP; Colletti M; Conti B; Marquez VE; Strillacci A; Roma J; Gallego S; Milano GM; Capogrossi MC; Bertaina A; Ciarapica R; Rota R
    Clin Epigenetics; 2015; 7(1):82. PubMed ID: 26251675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma.
    Huang SC; Alaggio R; Sung YS; Chen CL; Zhang L; Kao YC; Agaram NP; Wexler LH; Antonescu CR
    Am J Surg Pathol; 2016 Jul; 40(7):876-85. PubMed ID: 26872011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
    Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
    Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
    Belyea BC; Naini S; Bentley RC; Linardic CM
    Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.
    Bergantin E; Quarta C; Nanni C; Fanti S; Pession A; Cantelli-Forti G; Tonelli R; Hrelia P
    Cancer Biol Ther; 2014 Sep; 15(9):1219-25. PubMed ID: 24971463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Staufen1 controls mitochondrial metabolism via HIF2α in embryonal rhabdomyosarcoma and promotes tumorigenesis.
    Almasi S; SarmastiEmami S; Baird S; Ning Z; Figeys D; Côté J; Cowan KN; Jasmin BJ
    Cell Mol Life Sci; 2023 Oct; 80(11):328. PubMed ID: 37847286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma via c-myc-dependent and -independent events.
    Crawford Parks TE; Marcellus KA; Langill J; Ravel-Chapuis A; Michaud J; Cowan KN; Côté J; Jasmin BJ
    Sci Rep; 2017 Feb; 7():42342. PubMed ID: 28211476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
    Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
    Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
    Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
    J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice.
    Ecke I; Petry F; Rosenberger A; Tauber S; Mönkemeyer S; Hess I; Dullin C; Kimmina S; Pirngruber J; Johnsen SA; Uhmann A; Nitzki F; Wojnowski L; Schulz-Schaeffer W; Witt O; Hahn H
    Cancer Res; 2009 Feb; 69(3):887-95. PubMed ID: 19155313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.